Two recently published meta-reviews provide clear evidence that the HPV vaccine is linked to a massive reduction in cervical cancer risk. Moreover, the same studies provided more evidence that the HPV vaccine is safe.
Meta-reviews are considered the most powerful studies in biomedical science because they combine the results of multiple studies addressing a shared research question, providing the most precise estimates of treatment effects, risks, or associations. They resolve contradictions between studies, increase statistical power, especially for rare diseases, and drive clinical practice guidelines and healthcare policies. They are the foundation of evidence-based medicine.
So these meta reviews are extremely powerful scientific evidence that the HPV vaccine prevents cervical cancer and that it is extremely safe, despite the claims of the anti-vaccine world.
This post will examine these two studies and review what they tell us about the safety and effectiveness of the HPV vaccine.

All about HPV and the HPV vaccine
I know I cut and paste this section into every article I write about HPV vaccines, but it’s the first step to HPV vaccine myth debunking. Some readers may be researching the vaccine for the first time, and they can find out how the HPV vaccine reduces cancer risks.
However, I try to update this section when necessary with new information about either the disease or the vaccine. If you’ve read this section 47 times, skip to the next section where I discuss the key points of this article.
Genital and oral human papillomavirus (HPV) infections are the most common sexually transmitted infections (STIs) in the USA. HPV is generally transmitted from personal contact during vaginal, anal, or oral sex.
It is critical to note that there are more than 150 strains or subtypes of HPV that can infect humans; however, only 40 of these strains are linked to one or more different cancers. Moreover, of those 40 strains, most are fairly rare.
Although the early symptoms of HPV infections aren’t serious and many HPV infections resolve themselves without long-term harm, HPV infections are causally linked to many types of cancers in men and women. According to current medical research, here are some of the cancers that are linked to HPV:
- Cervical cancer
- Vulvar cancer
- Vaginal cancer
- Anal cancer
- Oropharyngeal cancer (throat cancer)
- Penile cancer
In addition, there is some evidence that HPV infections are causally linked to skin and prostate cancers. The link to skin cancer is still preliminary, but there is much stronger evidence that HPV is linked to many prostate cancers.
HPV is believed to cause nearly 5% of all new cancers across the world, making it almost as dangerous as tobacco in that respect. According to published research, roughly 42 million persons in the USA are infected with disease-associated HPV, and 13 million persons acquire a new infection each year.
Each year in the United States, about 47,984 new cases of cancer are found in parts of the body where human papillomavirus (HPV) is often found — 26,280 among females, and 21,704 among males.
Most individuals don’t even know they have the infection until the onset of cancer. The CDC states that over 37,800 HPV-related cancers are diagnosed in the USA every year. In 2022, there were approximately 1,505,394 HPV-related cancer cases and 755,303 deaths worldwide, with cervical cancer being the primary cause, accounting for 14.1 per 100,000 people.
There were two HPV vaccines on the world market before 2014. GSK, also known as GlaxoSmithKline, produced Cervarix, a bivalent vaccine that protects only against two HPV strains. Cervarix has been withdrawn from the US market (although available in many other markets) because of competition from the quadrivalent, which immunizes against four different HPV strains, and the 9-valent, which protects against nine HPV strains, Gardasil vaccines.
Merck manufactures Gardasil, probably the most popular HPV vaccine in the world. The first version of the vaccine, quadrivalent Gardasil, targets the two HPV genotypes known to cause about 70% of cervical cancer and two other HPV genotypes that cause genital warts. In Europe and other markets, Gardasil is known as Silgard.
The newer Gardasil 9, approved by the FDA in 2014, is a 9-valent vaccine that protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It targets the four HPV strains found in the quadrivalent version, along with five additional ones that are linked to cervical and other HPV-related cancers. Both versions of Gardasil are prophylactic, meant to be given to females or males before they become exposed to possible HPV infection through intimate contact.
Gardasil is one of the easiest and best ways to prevent a few dangerous and, to abuse the definition slightly, common cancers that afflict men and women. Without a doubt, the HPV vaccine prevents cancer.
In the United States, the Advisory Committee on Immunization Practices (ACIP) currently recommends that preteen girls and boys aged 11 or 12 receive the HPV vaccine. The HPV vaccine is also recommended for teenage girls and young women up to the age of 26 who did not receive it when they were younger, and boys and young men up to the age of 21.
HPV is a sexually transmitted disease. HPV causes 37,800 cancers a year in the USA and over 1.5 million worldwide. The HPV vaccine prevents one from becoming infected by HPV, which means you are protected from these cancers.

HPV vaccine and cervical cancer risk — first paper
In a meta-analysis published on 24 November 2025 in the Cochrane Database of Systematic Reviews, Hannah Bergman, MSc, Cochrane Response, London, UK, and colleagues developed a meta-analysis of 225 observational studies involving more than 132 million people, specifically females aged 16 years or younger who received HPV vaccines.
Here are the key results:
- Women who received the HPV vaccines were 80% less likely than their unvaccinated counterparts to develop cervical cancer.
- Long-term cervical cancer risk after HPV vaccination fell 63% based on adjusted estimates from five cohort studies with nearly 4.4 million females.
- Evidence from 23 studies showed with moderate certainty that HPV vaccination lowered the incidence of cervical intraepithelial neoplasia grade 3 or higher (CIN3+).
- In two cohort studies that included 1.5 million females vaccinated by age 16 years, the long-term incidence of CIN3+ fell by 74%.

HPV vaccine and cervical cancer risk — second paper
In a second meta-analysis published on 24 November 2025 in the Cochrane Database of Systematic Reviews, Nicholas Henschke, PhD, Cochrane Response, Berlin, Germany, and colleagues included 60 randomized controlled trials (RCTs) with 157,414 participants.
Here are the key results of the meta-analysis:
- In females aged 15-25 years, vaccination was linked to a 30% reduction in CIN2+ after 6 years, regardless of HPV type.
- CIN2+ risk from vaccine-matched HPV types fell 60% after 6 years.
- Three randomized controlled clinical trials with 21,271 participants showed 25 fewer cases of anogenital warts per 1,000 vaccinated participants, regardless of HPV type, at 48 months.
- The observational-study analysis across 47 studies likewise showed a 47% reduced risk of anogenital warts over 12 months to five years, and a 53% drop with follow-up beyond five years.

HPV vaccine safety
The two meta-analyses also examined the overall safety of the HPV vaccine. This is what the studies found:
- Both meta-analyses showed HPV vaccination wasn’t linked to a greater number of serious adverse events. Among 39 RCTs with 97,272 participants, the HPV vaccinated groups showed little difference compared with controls in rates of serious adverse events at up to 72 months.
- HPV vaccination wasn’t associated with increased risk of a range of adverse events commonly blamed on the vaccines.
Summary
These two meta-analyses provide formidable evidence that the HPV vaccine substantially reduces the risk of cervical cancer and pre-cancerous CIN. I keep reading demands that we find a cancer vaccine, and here we are, a cancer vaccine that reduces the risk of cervical cancer. With further research, I’m sure we will find that the vaccine reduces the risks for other HPV-related cancers.
Moreover, these studies provide equally powerful evidence that the HPV vaccine is extraordinarily safe.
These studies represent the pinnacle of the hierarchy of scientific research, and their conclusions are clear.
Parents who want to protect their children from HPV-related cancers should run, not walk, to their healthcare provider to get the vaccine at the appropriate age. Even older children and young adults will benefit from the cancer-preventing HPV vaccine.
Citations
- Bergman H, Henschke N, Arevalo-Rodriguez I, Buckley BS, Crosbie EJ, Davies JC, Dwan K, Golder SP, Loke YK, Probyn K, Petkovic J, Villanueva G, Morrison J. Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. Cochrane Database Syst Rev. 2025 Nov 24;11(11):CD015364. doi: 10.1002/14651858.CD015364.pub2. PMID: 41276263; PMCID: PMC12640750.
- Henschke N, Bergman H, Buckley BS, Crosbie EJ, Dwan K, Golder SP, Kyrgiou M, Loke YK, McIntosh HM, Probyn K, Villanueva G, Morrison J. Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination. Cochrane Database Syst Rev. 2025 Nov 24;11(11):CD015363. doi: 10.1002/14651858.CD015363.pub2. PMID: 41276264; PMCID: PMC12640735.
- Lewis RM, Laprise JF, Gargano JW, Unger ER, Querec TD, Chesson HW, Brisson M, Markowitz LE. Estimated Prevalence and Incidence of Disease-Associated Human Papillomavirus Types Among 15- to 59-Year-Olds in the United States. Sex Transm Dis. 2021 Apr 1;48(4):273-277. doi: 10.1097/OLQ.0000000000001356. PMID: 33492097; PMCID: PMC10037549.
Help the Skeptical Raptor keep writing about vaccine facts
There are four ways you can help contribute to keeping this website running at full speed:
Discover more from Skeptical Raptor
Subscribe to get the latest posts sent to your email.
